F. Michael Yakes

7.9k total citations · 4 hit papers
20 papers, 5.9k citations indexed

About

F. Michael Yakes is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, F. Michael Yakes has authored 20 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 10 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in F. Michael Yakes's work include PI3K/AKT/mTOR signaling in cancer (7 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Mechanisms and Therapy (4 papers). F. Michael Yakes is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (7 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Mechanisms and Therapy (4 papers). F. Michael Yakes collaborates with scholars based in United States, Spain and United Kingdom. F. Michael Yakes's co-authors include Bennett Van Houten, Carlos L. Arteaga, Incheol Shin, Christoph A. Ritter, Stacy L. Moulder, Roberto Bianco, José Baselga, Andrei V. Bakin, Federico Rojo and Jean F. Simpson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and The Journal of Cell Biology.

In The Last Decade

F. Michael Yakes

20 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress

1997 1.5k citations F. Michael Yakes, Bennett Van Houten Proceedings of the National Academy of Sciences profile →
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

2011 1.0k citations F. Michael Yakes, Jason Chen et al. Molecular Cancer Therapeutics profile →
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization

2002 642 citations Incheol Shin, F. Michael Yakes et al. Nature Medicine profile →
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

2002 506 citations F. Michael Yakes, Wichai Chinratanalab et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Michael Yakes United States	15	3.4k	2.3k	1.1k	679	652	20	5.9k
Anderson J. Ryan United Kingdom	42	3.9k 1.1×	2.9k 1.3×	1.4k 1.2×	1.5k 2.2×	715 1.1×	159	7.4k
Eliot M. Rosen United States	57	4.7k 1.3×	1.8k 0.8×	999 0.9×	1.2k 1.8×	480 0.7×	145	7.9k
Floriana Morgillo Italy	44	3.1k 0.9×	3.1k 1.4×	2.0k 1.8×	1.2k 1.8×	327 0.5×	161	6.6k
Stefano Pepe Italy	45	2.6k 0.8×	2.5k 1.1×	1.1k 1.0×	647 1.0×	299 0.5×	130	5.3k
Zhen Fan United States	37	2.5k 0.7×	3.0k 1.3×	1.4k 1.3×	1.0k 1.5×	845 1.3×	70	5.6k
Hiroyuki Kato Japan	38	2.7k 0.8×	1.9k 0.8×	1.2k 1.1×	861 1.3×	231 0.4×	243	5.4k
Alfredo Budillon Italy	50	3.7k 1.1×	2.6k 1.1×	974 0.9×	1.1k 1.7×	471 0.7×	203	6.7k
Jiping Zha United States	26	6.2k 1.8×	1.9k 0.8×	823 0.7×	1.0k 1.5×	174 0.3×	43	8.1k
William P. Bennett United States	35	2.5k 0.7×	2.0k 0.9×	774 0.7×	1.3k 1.9×	200 0.3×	62	5.0k
Juliane M. Jürgensmeier United States	30	3.7k 1.1×	1.3k 0.5×	533 0.5×	738 1.1×	194 0.3×	69	5.4k

Countries citing papers authored by F. Michael Yakes

Since Specialization

Citations

This map shows the geographic impact of F. Michael Yakes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Michael Yakes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Michael Yakes more than expected).

Fields of papers citing papers by F. Michael Yakes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Michael Yakes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Michael Yakes. The network helps show where F. Michael Yakes may publish in the future.

Co-authorship network of co-authors of F. Michael Yakes

This figure shows the co-authorship network connecting the top 25 collaborators of F. Michael Yakes. A scholar is included among the top collaborators of F. Michael Yakes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Michael Yakes. F. Michael Yakes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Han-Jie, Jinhai Wang, Bing Yao, et al.. (2015). Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). Journal of Medicinal Chemistry. 58(24). 9480–9497. 146 indexed citations

Moigne, Ronan Le, Steve Wong, Ferdie Soriano, et al.. (2014). Abstract 951: CB-5083 is a novel first in class p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models. Cancer Research. 74(19_Supplement). 951–951. 1 indexed citations

Bentzien, Frauke, Yongchang Shi, Peiwen Yu, et al.. (2013). In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer. Thyroid. 23(12). 1569–1577. 102 indexed citations

Yakes, F. Michael, Jason Chen, Jenny Tan, et al.. (2011). Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth. Molecular Cancer Therapeutics. 10(12). 2298–2308. 1036 indexed citations breakdown →

Qian, Fawn, Stefan Engst, Toshihiro Yamaguchi, et al.. (2009). Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases. Cancer Research. 69(20). 8009–8016. 282 indexed citations

Bianco, Roberto, Incheol Shin, Christoph A. Ritter, et al.. (2003). Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 22(18). 2812–2822. 357 indexed citations

Arteaga, Carlos L., Stacy L. Moulder, & F. Michael Yakes. (2002). HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Seminars in Oncology. 29(3). 4–10. 67 indexed citations

Yakes, F. Michael, Wichai Chinratanalab, Christoph A. Ritter, et al.. (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.. PubMed. 62(14). 4132–41. 506 indexed citations breakdown →

Shin, Incheol, F. Michael Yakes, Federico Rojo, et al.. (2002). PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nature Medicine. 8(10). 1145–1152. 642 indexed citations breakdown →

10.

Arteaga, Carlos L., Stacy L. Moulder, & F. Michael Yakes. (2002). HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Seminars in Oncology. 29(3 Suppl 11). 4–10. 45 indexed citations

11.

Sobol, Robert W., David E. Watson, Jun Nakamura, et al.. (2002). Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress. Proceedings of the National Academy of Sciences. 99(10). 6860–6865. 76 indexed citations

12.

Lenferink, Anne E.G., Dagmar Busse, W. Michael Flanagan, F. Michael Yakes, & Carlos L. Arteaga. (2001). ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.. PubMed. 61(17). 6583–91. 156 indexed citations

13.

Muraoka, Rebecca S., Anne E.G. Lenferink, Jean F. Simpson, et al.. (2001). Cyclin-Dependent Kinase Inhibitor P27Kip1 Is Required for Mouse Mammary Gland Morphogenesis and Function. The Journal of Cell Biology. 153(5). 917–932. 67 indexed citations

14.

Moulder, Stacy L., F. Michael Yakes, Senthil K. Muthuswamy, et al.. (2001). Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.. PubMed. 61(24). 8887–95. 465 indexed citations

15.

Bardhan, S., Barbara D. Wamil, Yibo Wang, et al.. (2001). Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis.. PubMed. 7(12). 4182–94. 10 indexed citations

16.

Busse, Dagmar, F. Michael Yakes, Anne E.G. Lenferink, & Carlos L. Arteaga. (2001). Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance. Seminars in Oncology. 28(5N). 47–55. 1 indexed citations

17.

Yakes, F. Michael, et al.. (2000). CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis.. PubMed. 60(20). 5740–6. 13 indexed citations

18.

Ballinger, Scott W., Cam Patterson, Richard Doan, et al.. (2000). Hydrogen Peroxide– and Peroxynitrite-Induced Mitochondrial DNA Damage and Dysfunction in Vascular Endothelial and Smooth Muscle Cells. Circulation Research. 86(9). 960–966. 385 indexed citations

19.

Yan, Heping, Clint E. Carter, Enze Wang, et al.. (1998). Functional studies on the anti-pathoangiogenic properties of CM101. Angiogenesis. 2(3). 219–233. 11 indexed citations

20.

Yakes, F. Michael & Bennett Van Houten. (1997). Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proceedings of the National Academy of Sciences. 94(2). 514–519. 1496 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact